---
title: "ACADIA Pharmaceuticals (ACAD) Receives a Hold from Stifel Nicolaus"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293825186.md"
description: "Stifel Nicolaus analyst Paul Matteis maintained a Hold rating on ACADIA Pharmaceuticals (ACAD) with a $25.00 price target. While Matteis focuses on the Healthcare sector, the broader market consensus for ACAD is a Moderate Buy with an average price target of $32.43."
datetime: "2026-07-25T14:45:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293825186.md)
  - [en](https://longbridge.com/en/news/293825186.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293825186.md)
---

# ACADIA Pharmaceuticals (ACAD) Receives a Hold from Stifel Nicolaus

In a report released today, Paul Matteis from Stifel Nicolaus maintained a Hold rating on ACADIA Pharmaceuticals, with a price target of $25.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Matteis covers the Healthcare sector, focusing on stocks such as Definium Therapeutics, ACADIA Pharmaceuticals, and Alkermes. According to TipRanks, Matteis has an average return of 17.8% and a 53.75% success rate on recommended stocks.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ACADIA Pharmaceuticals with a $32.43 average price target.

### Related Stocks

- [ACAD.US](https://longbridge.com/en/quote/ACAD.US.md)
- [SF.US](https://longbridge.com/en/quote/SF.US.md)
- [DFTX.US](https://longbridge.com/en/quote/DFTX.US.md)
- [ALKS.US](https://longbridge.com/en/quote/ALKS.US.md)
- [SF-C.US](https://longbridge.com/en/quote/SF-C.US.md)
- [SFB.US](https://longbridge.com/en/quote/SFB.US.md)
- [SF-B.US](https://longbridge.com/en/quote/SF-B.US.md)
- [SF-D.US](https://longbridge.com/en/quote/SF-D.US.md)

## Related News & Research

- [Acadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference | ACAD Stock News](https://longbridge.com/en/news/294422717.md)
- [How FDA Fast Track For Remlifanserin In Alzheimer’s Psychosis At ACADIA (ACAD) Has Changed Its Investment Story](https://longbridge.com/en/news/294004149.md)
- [The Manufacturers Life Insurance Company Raises Stock Holdings in ACADIA Pharmaceuticals Inc. $ACAD](https://longbridge.com/en/news/294668349.md)
- [How investors can navigate the healthcare sector](https://longbridge.com/en/news/293960711.md)
- [Stifel Nicolaus Remains a Buy on Biogen (BIIB)](https://longbridge.com/en/news/294611264.md)